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Abstract 
A recent advance in anti-cancer therapies has been the use of cancer cells to develop vaccines. 
However, immunization with cancer cell-based vaccines has not resulted in significant 
long-term therapeutic benefits. A possible reason for this is that while cancer cells provide 
surface antigens that are targets for a desired immune response, they also contain a high 
abundance of housekeeping proteins, carbohydrates, nucleic acids, lipids, and other intra-
cellular contents that are ubiquitous in all mammalian cells. These ubiquitous molecules are 
not the intended targets of this therapy approach, and thus, the immune response generated 
is not sufficient to eliminate the cancer cells present. In this review, a discussion of the cell 
surface of cancer cells is presented in relation to the goals of improving antigen composition 
of cancer cell-based vaccines. Strategies to enrich vaccines for cancer-specific antigens are 
also discussed. 
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Advantages and disadvantages of cancer 
cell-based vaccines 
The efficacy of whole-cell cancer vaccines has 
been investigated for more than 20 years in both 
preclinical models and in clinical trials in humans 
(1-3). The advantages of whole-cell vaccination over 
other types of immunotherapy that target specific 
antigens, is that multiple and unknown antigens may 
be targeted by both the innate and adaptive immune 
system. However, immunization with whole-cell vac-
cines has not resulted in significant long-term thera-
peutic benefits (4, 5). One possible explanation is that 
only a small proportion of the molecules expressed on 
the cell surface are specific to cancer cells, while the 
vast majority of cellular constituents derive from 
housekeeping genes, carbohydrates, nucleic acids, 
lipids, and other molecules that are ubiquitously ex-
pressed by normal cells (6). As a result, the immune 
response generated in patients administered vaccines 
generated from whole cancer cells is insufficient to 
eliminate the cancer cells present in vivo. Therefore, 
further improvements are necessary to improve the 
specificity of cancer cell-based vaccines.  
Ideally, vaccines developed to treat cancer need 
to recognize molecules that are not found on un-
transformed cells (7-11). Surface antigens, proteins, 
and associated carbohydrates, are the targets natu-
rally accessible to surveillance by the immune system, 
particularly by the humoral and cellular immune re-
sponse. However, when whole cells are used for the 
preparation of vaccines, a greater proportion of 
intracellular molecules are combined with a smaller 
proportion of cell surface-associated molecules, the-
reby reducing the concentration of cancer cell-specific 
antigens recognized for vaccine production (Figure 1). 
Therefore, cancer cells used for the development of 
vaccines contain a high proportion of targets which Journal of Cancer 2010, 1 
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are not cancer cell-specific, and an enrichment of cell 
surface material is needed to improve the effective-
ness of cancer vaccines. 
 
 
Figure 1. Ratios of the categories of cell surface targets which are accessible for humoral and cytotoxic immunity. Figure 
adapted from (118). 
 
Cell surface molecules and cancer immunity 
The recognition of antigens during cell-cell inte-
ractions plays an important role in immune function. 
For example, it is through cell-cell interactions that 
cancer cells are recognized and targeted for cell lysis 
by effector cells. Correspondingly, cancer cells have 
developed strategies to prevent their recognition and 
adhesion by immune effector cells. One way they 
h a v e  d o n e  t h i s  i s  t o  m a i n t a i n  a  c e l l  s u r f a c e  t h a t  i s  
lacking immunodominant antigens (12, 13). Moreo-
ver, cancer cells present substances with immuno-
suppressive properties (14-19). For example, tenas-
cin-C extracts from a glioma cell line inhibit T lym-
phocyte proliferation and cytokine production 
(20-22). Other studies have also demonstrated that 
glioma cells produce thick glycosaminoglycan coats to 
protect them from cytotoxic T-lymphocyte (CTL) 
responses (23-25). Galectins are another class of cell 
surface molecules which have been shown to have 
important roles in the survival, angiogenesis, and 
metastasis of tumors (26, 27). Furthermore, less cha-
racterized cell surface molecules have also been 
shown to have immunosuppressive characteristics. 
For example, highly malignant lymphoma cells 
(RAW117) have been shown to inhibit both T-cell and 
B-cell mitogen-induced proliferation of normal mu-
rine spleen cells. Interestingly, a similar inhibition was 
observed when RAW117 cells were extracted with 
butanol (28), and this extract was used instead of 
whole RAW117 cells (29). In another study where cell 
surface molecules from lymphoma cells were ex-
tracted with butanol, an inhibitory effect of this ex-
tract on natural killer and lymphokine activated killer 
cell mediated cytotoxicity was also observed (30).  
In combination, these findings demonstrate that 
the cell surface of cancer cells lack immunodominant 
antigens, and predominantly consist of molecules 
with immunosuppressive properties. 
Cell surface proteins and cancer antigenicity 
Despite the immunosuppressive activity asso-
ciated with some cell surface molecules of cancer cells, 
antigenic motifs are also present. The ability of these 
two functions to co-exist on the surface of cancer cells 
has been investigated. For example, antibodies pro-
duced by a host organism in response to injected cells 
were found to selectively and specifically bind the 
antigenic targets of the injected cells (31-33). In 
another approach, cell surface molecules were re-
moved with 0.2% trypsin, and cell antigenicity was 
subsequently examined (34). Trypsinization has pre-
viously been reported to release glycoproteins and 
sugars from the cell surface (35-38) (Figure 2), thereby 
leading to a loss of antigenic properties (39-42). In 
particular, Takeichi et al. showed that trypsin treat-
ment of SV40-transformed 3T3 cells decreased their 
antigenicity in footpad assays (42). Similarly, Molinari 
and Platt (43) demonstrated that polyoma vi-
rus-transformed cells treated with trypsin failed to 
induce a delayed hypersensitivity reaction against 
tumor-specific antigens in footpad swelling assays. In Journal of Cancer 2010, 1 
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other studies, Fakhri and Tan (44) reported that 
treatment of mouse plasmacytomas with 1% trypsin 
decreased the number of antigenic determinants 
present. Further experiments using mixtures of nor-
mal and sensitive cells also suggest that trypsin al-
tered an immunologic capacity of the sensitive cells 
assayed (39). For example, peritoneal exudate cells 
from animals exhibiting delayed hypersensitivity 
were associated with a decrease in migration in vitro. 
However, this effect on migration was completely 
abolished when these cells were pretreated with 
trypsin. In combination, these data demonstrate that 
antigenic targets are present on the surface of cancer 
cells, since the removal of molecules from the cell 
surface results in a decrease in antigenicity. 
 
 
Figure 2. Ruthenium staining of the cell surface of a normal rat brain cell (a) and a malignant rat neurogenic cell (b). 
Magnification, 40,000x. Figures adapted from (119). (c) Partial detachment of cell surface material (indicated with a red 
arrow) following treatment of the cell with 0.2% trypsin. Magnification, 19,000x. Figure adapted from (34). 
 
Strategies for improving cancer cell-based 
vaccines 
The contamination of intracellular material in the 
development of cancer cell-specific vaccines, and 
evidence regarding the presence of antigenic proper-
ties on the surface of cancer cells, have been pre-
sented. Based on these considerations, it would be 
advantageous to isolate the cell surface molecules of 
cancer cells to develop vaccines rather than using 
whole cell preparations. Correspondingly, the cancer 
cell-specificity of vaccines using cell surface antigens Journal of Cancer 2010, 1 
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would be improved without a loss of native antigen 
diversity. Vaccination with the fraction of soluble 
membrane antigens of cancer cells was proposed by 
Hollinshead et al. many years ago (45-48). However, 
this vaccine development approach has not resulted 
in vaccines approved for human use. Therefore, here 
we emphasize new approach which based on vaccine 
development using proteolitycally-cleved cell surface 
antigens. Although the isolation of cell surface mole-
cules using proteases was described many years ago 
(42, 49-53), as well as the use of cancer cells for vacci-
nation, limitations in the applicability of such an ap-
proach have evolved to include considerations of 
protease purity and cellular damage incurred during 
protease treatments and antigen preparations. 
Antigen pollution associated with protease 
impurity 
One of the earliest studies of trypsinization of 
tumor cells was conducted in 1958, and a significant 
loss of tumor mass (up to 20%) was induced without 
any apparent change in cell viability (54). Subsequent 
studies of cell-disaggregating agents and cell integrity 
used suspension cells (55-57) or cells from intact tissue 
(58, 59). In both cases, integrity of the treated cells 
following trypsinization was sufficient to maintain 
the viability of the cells (54, 56, 60, 61). However, there 
have been other methods described for the disaggre-
gation of intact tissues that has been shown to cause 
considerable damage to the cell (58). In an investiga-
tion by Anghilery and Dermietzel, trypsinization was 
shown to liberate up to 10% of cell material, which 
contained significant amounts of lipid and nucleic 
acids from intracellular lipo- and nucleoproteins (50). 
When a mild treatment of cells with 0.1% trypsin was 
performed, up to 10.4% of cellular RNA and 11.4% of 
cellular DNA were obtained, consistent with a lysis 
rate of ~11% (62). However, when a higher purity 
trypsin was used, less than 2% of cells were lysed (63). 
Based on these results, trypsin impurities were 
identified as a cause of increased cell damage. In more 
recent studies where highly-purified trypsin with an 
activity of 15 000 U/mg was used, rates of cell lysis 
were less then 0.1% (Figure 3) (64). Therefore, mam-
malian cells can be treated with trypsin without in-
ducing the lysis of the treated cells, if highly purified 
trypsin is used. 
Another aspect to consider regarding the use of 
unpurified trypsin is the possibility that the antigens 
collected will be contaminated with the trypsin used. 
Trypsin at a working concentration of ~300 µg/ml has 
previously been widely used in scientific experiments 
to cleave cell surface material (49, 65). For example, a 
recent study showed that the treatment of 5 ml of 
cancer cells with 1 ml of trypsin solution yielded only 
10-20 µg of cell surface (glyco)protein fragments (64). 
This represents ~1% of the total protein content of a 
cell. Based on these results and others, the consensus 
of the data indicate that the concentration of trypsin 
used to cleave cell surface antigens significantly ex-
ceeds that of the cleaved cell surface antigens. Cor-
respondingly, since trypsin contains numerous im-
purities, including other types of proteases, diffe-
rently degraded forms of trypsin, and trypsin autoly-
sis products (66), identification of the cell surface an-
tigens treated with trypsin requires complex analyti-
cal methods, and these have been described (49, 52, 
67-75). However, the need for antigen identification is 
more relevant to the characterization of individual 
antigens than for vaccine production. Thus, for vac-
cine production, it is important that highly purified 
trypsin be used in the preparation of cell surface pro-
teins for vaccination. Correspondingly, it has recently 
been demonstrated that live cells treated with high-
ly-purified trypsin resulted in a solution of cell spe-
cific peptides which were not contaminated with 
proteases, cytosolic proteins, or serum from the cell 
growth medium (76). Therefore, these results confirm 
that highly-purified trypsin can provide a high purity 
sample of cell surface antigens.  
Antigen pollution associated with cell dam-
age 
The mechanism by which trypsin acts has been 
very well characterized. However, the cell damage 
that occurs as a result of treatment with proteases also 
includes cell damage generated by fluid shearing. It 
has been established that animal cells are sensitive to 
fluid shearing in serum-free medium (77-81). How-
ever, to obtain pure samples of cell surface antigens, 
cells are prepared in serum-free medium. As a result, 
damage of the cell membrane leads to the release of 
intracellular contents. As shown in Figure 1, the 
amount of cell surface antigens obtained from 100 
cancer cells is comparable to the quantity of intracel-
lular molecules contained within a single cell. In work 
by Lau and Tchao (2007) using Nara Bladder Tumour 
(NBT) II cells, if cells were grown on plastic surfaces 
vs. glass surfaces, the amount of cell damage due to 
fluid shear was 56% and 5%, respectively (79). 
Therefore, a critical aspect of preparing cell surface 
a n t i g e n s  i s  t o  m i n i m i z e  t h e  d e s t r u c t i o n  o f  c e l l s  b y  
fluid shearing. Correspondingly, when protocol con-
ditions were optimized and careful manipulation of 
the cells was maintained, an observed death rate of < 
0.1% of adenocarcinoma cells was achieved following 
trypsinization (64) (Figure 3). For cell cultures that are 
more sensitive to fluid shear, an optimization of cell Journal of Cancer 2010, 1 
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growth conditions and an application of cy-
to-protectants may be needed to prevent cell damage 
in serum-free medium and to decrease the rate of cell 
death during manipulations (77).  
Thus, the careful treatment of live cells with 
highly purified proteases facilitates the collection of 
cell surface antigens with minimal contamination by 
undesired intracellular contents. Figure 4 summarizes 
the influence of protease impurities and cell death 
rates associated with fluid shearing on the purity of 
cell surface antigens collected. 
 
 
Figure 3. Human breast adenocarcinoma cells (MCF-7) are shown before (a) and after (b) treatment with trypsin (0.2 
µg/mL, activity 15000 U/mg) for 25 min. In situ trypan blue staining was performed, and cells that are stained represent dead 
cells (see arrow). Images were obtained using an inverted phase contrast microscope (scale bar: 50 µm). Figure adapted from 
Balashova et al. (64). 
 
Figure 4. Effects of trypsin impurity and cell death rate on the preparation of cell surface antigens. The lighter region in the 
lower left corner represents conditions where cell-surface antigen preparations are compatible with the preparation of 
vaccines. Trypsin purity is reflected in the levels of enzymatic activity. Adapted from Lokhov (118).  
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Proof-of-concept studies using cancer cells 
To confirm that proteolytically-cleaved cell sur-
face antigens are sufficient for developing effective 
vaccines, immunogenic properties of cell surface an-
tigens and whole cancer cells were examined. In cy-
totoxicity assays, human CTLs were incubated with 
target adenocarcinoma cells, MCF-7 (64), and CTLs 
were stimulated with dendritic cells loaded with cell 
surface antigens or whole cancer cells. In these assays, 
cell surface antigens were 10-40% more effective at 
inducing cytotoxicity than the whole cell lysates 
(Figure 5) (64). Moreover, the total protein concentra-
tion of the whole cell lysates vs. the cell surface anti-
gen preparations was 270 µg/mL vs. 2 µg/mL, re-
spectively. Therefore, the higher levels of cytotoxicity 
that were associated with a significantly lower protein 
concentration demonstrates the importance of anti-
genic targets being free from intracellular contami-
nants for effective immune response stimulation. 
Correspondingly, the authors concluded that these 
results provided a proof-of-concept that the proteo-
lytic treatment of live cancer cells can release anti-
genic targets that are sufficient to induce an an-
ti-cancer immune response that exceeds that of un-
treated cancer cells in vitro. As a result, further studies 
will be needed to more completely characterize the 
use of cell surface antigens instead of whole cancer 
cell preparations in the generation of anti-cancer vac-
cines.  
 
 
Figure 5. A comparison of whole cell lysates and proteolytically-cleaved cell surface antigens in mediating the lysis of breast 
adenocarcinoma cells in cytotoxicity assays. Target adenocarcinoma cells, MCF-7, were incubated with effector CTLs at a 
ratio of 4:1. On the 3
rd day, target cells were carefully washed and imaged using an inverted phase contrast microscope (scale 
bar: 50 µm). (a) Initial cell culture of MCF-7 cells. (b) Control MCF-7 cells grown alone. (c) MCF-7 cells incubated with CTLs 
that had been stimulated with dendritic cells loaded with whole cell lysates. (d) MCF-7 incubated with CTLs that had been 
stimulated with dendritic cells loaded with cell surface antigens. Cell surface antigens show the same ability to induce cy-
totoxic activity in CTLs as whole cell lysates. Adapted from Balashova et al. (64).  Journal of Cancer 2010, 1 
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Figure 6. CTL-mediated lysis of human microvascular endothelial cells (HMEC) produced by whole cell lysates or cell 
surface antigens of HMEC in cytotoxicity assays. HMEC (40 000 cells/well) were incubated with effector cytotoxic T 
lymphocytes (CTL) at a ratio of 1:8 and were imaged using an inverted phase contrast microscope. (a) Initial cell culture of 
HMEC. (b) HMEC incubated with CTL stimulated, unloaded antigen-presenting cells. (c) HMEC incubated with CTL sti-
mulated, antigen-presenting cells loaded with HMEC lysate. (d) HMEC incubated with CTL stimulated, antigen-presenting 
cells loaded with cell surface antigens prepared from HMEC. Cell surface antigens are more effective at stimulating immune 
cells in cytotoxicity assays than whole cell HMEC lysates. Adapted from Balashova et al. (100). 
 
Proof-of-concept studies using endothelial 
cells 
It is known that tumor endothelial cells actively 
form new blood vessels, and this additional vascular 
capacity is essential for tumor growth and metastasis 
(82-88). Tumor-associated endothelial cells proliferate 
in response to tumor-secreted stimulators and un-
dergo changes in phenotype as needed. These pro-
nounced changes distinguish them from endothelial 
cells of the normal vasculature (89-92). While many 
studies have shown that cancer cells provide antigens 
suitable for inducing an immune-targeted response (2, 
3, 93), a similar approach has been proposed for the 
use of endothelial cells to develop cellular an-
ti-angiogenic, anti-cancer vaccines. This approach was 
previously shown to inhibit the growth of experi-
mental tumors in mouse models (94-99). However, 
endothelial cell-based vaccines share a similar limita-
tion with cell-based vaccines in that the extracellular 
macromolecules of endothelial cells include both an-
tigens and ubiquitously expressed proteins that are 
common to all mammalian cells, including normal 
endothelial cells. Therefore, the ability to isolate 
extracellular protein targets important for both hu-
moral and cell-mediated immune responses by 
treatment of endothelial cells with proteases was a 
proposed strategy for the creation of anti-angiogenic 
vaccines, and was tested using primary cultures of 
human microvascular endothelial cells (HMECs) 
(100). With careful manipulation and use of a high-
ly-purified protease, cell surface antigens, as well as 
whole cell lysates were obtained. These buffered so-
lutions had a total protein concentration of 135 
µg/mL and 2 µg/mL, respectively. However, despite 
this difference in concentration, cell surface antigen 
preparations induced more cytotoxicity than the 
whole cell lysates. Moreover, surface antigens ob-
tained from tumor-activated endothelial cells were 
able to stimulate an immune response toward tu-
mor-activated endothelial cells. Based on these re-
sults, the authors concluded that surface antigens of 
endothelial cells appear to be able to induce targeted, 
immune-mediated cytotoxic effects against tumor 
endothelial cells, and these results demonstrate the 
potential for endothelial surface antigens, instead of 
whole endothelial cells, to generate anti-angiogenic 
anti-cancer vaccines.  Journal of Cancer 2010, 1 
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Authentication of cell surface antigens 
Cultivated cell studies have indicated that 
cross-contamination between cell lines is widely pre-
valent and continues to be a major problem (101-105). 
Based on current estimates, up to 36% of cell lines 
appear to have a different origin than their initial cell 
lines (105, 106). Moreover, cultivated mammalian cells 
have a finite mitotic lifespan (107-109), which is fol-
lowed by cellular degeneration and modifications of 
their cell surface profile (110, 111). Most existing cell 
lines have been passaged extensively in vitro, and 
therefore, considerable variation and genomic insta-
bility have been introduced (112, 113). Moreover, even 
cell lines that have been in culture for a relatively brief 
period of time, have displayed marked differences 
from the cultures derived from the same specimen 
( 1 1 4 ) .  T h i s  h e t e r o g e n e i t y  i s  p r o n o u n c e d  a t  t h e  g e -
nomic level, and is reflected in antigen expression 
patterns. It is hypothesized that these changes 
represent a cellular response to in vitro selection 
pressures (114), which can subsequently lead to a di-
vergence of cellular phenotypes over time.  
Accordingly, cultivated cancer cells intended for 
therapy, or for the isolation of antigens, must be au-
thenticated and analyzed for changes in surface anti-
gen expression. Cancer vaccines which are already in 
clinical trials (115) have not completed these analyses, 
partly because there is no routine method established 
for the analysis the diversity of cell surface proteins. 
In contrast, proteolytically-separated cell surface an-
tigens can be easily analyzed using mass spectrome-
try. This technique is related to 'proteomic footprint-
ing' that can be performed for cells, and represents a 
simple approach for the authentication and characte-
rization of cells. Furthermore this method is asso-
ciated with a rapid turnover time for samples and a 
low per sample cost (76). By comparing the composi-
tion of cell surface antigens obtained with a proteomic 
footprint of the reference cancer cells, the origin of the 
cell surface antigens obtained can be easily authenti-
cated (Figure 7). Moreover, any divergence in this 
comparison can reveal changes in antigen composi-
tion that may have occurred.  
 
 
 
Figure 7. Clustering of mass spectra data for cell surface antigens cleaved from fibroblasts of different origins. Fibroblast 
cultures were treated with trypsin under noncytolytic conditions. Mass spectra, or cell proteomic footprints, are 
represented in log scale and in binary format, where a dash indicates the presence of a measured peptide mass in the 
corresponding footprint. Footprints were clustered using the Ward method and according to the origin of the fibroblast 
culture analyzed. Therefore, cultures with unknown origins can be easily authenticated by identifying their relation to a 
footprint of a particular cluster. Adapted from Lokhov et al. (76).  
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Safety of cell surface antigens 
A potential limitation of current cell-based vac-
cines is the difficulty associated with purifying cells 
from dangerous contaminants such as cell parasites, 
viruses, toxins, and prions. Improving this aspect is 
essential for cell-based vaccines (116, 117). Given that 
proteolytically-cleaved cell surface antigens include 
(glyco)peptides, it is possible that ultrafiltration of 
these preparations could remove macromolecules and 
supramolecular structures to render the antigen 
preparations safe.  
Conclusions 
Accumulated data regarding the isolation of cell 
surface antigens from cancer cells has led to the fol-
lowing conclusions:  
•  The surface of cancer cells lack immunodomi-
nant antigens yet maintain immunosuppressive 
properties; 
•  Antigenic properties of cancer cells are mediated 
by cell surface molecules; 
•  Treatment of cells with proteases remove anti-
gens from cancer cells; 
•  Use of highly-purified trypsin and careful ma-
nipulation of cells allows cell surface antigens to 
be obtained with minimal contamination; 
•  Cell protectants are necessary to obtain cell sur-
face antigens from cancer cells that are sensitive 
to fluid shearing; 
•  The use of cell surface antigens, rather than 
whole cell preparations, to develop vaccines may 
improve the detection of cancer cells by the im-
mune system; 
•  By releasing cell surface antigens from the sur-
face of cells with proteases, the antigens obtained 
are free from dangerous contaminants associated 
with whole cell preparations such as cell para-
sites, viruses, toxins and prions. 
The efficiency of using cell surface antigens to 
generate anti-cancer vaccines is currently being eva-
luated, as well as the efficacy of using cell surface an-
tigens for the targeting of cancer cells by the immune 
response in humans. Currently, there are numerous 
clinical trials in progress that are based on the use of 
cancer cell-based vaccines (115), although these vac-
cines are not approved for human use. However, the 
diversity of native cancer antigens available from the 
use of cancer cells, the low levels of undesirable anti-
gens and dangerous intracellular agents that can be 
achieved with current methods, and the ability to 
authenticate antigens present, demonstrates the po-
tential for using cell surface antigens to develop safer 
and more effective cellular cancer vaccines.  
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